These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34386930)

  • 1. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
    Liu W; Liu R; Yuan R; Wang X
    Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 3. miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway.
    Wan J; Ling X; Peng B; Ding G
    Oncol Rep; 2018 Jul; 40(1):272-282. PubMed ID: 29767245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
    Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
    Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDL1 targeting by miR-138-5p amplifies anti-tumor immunity and Jurkat cells survival in non-small cell lung cancer.
    Rostami F; Tavakol Hamedani Z; Sadoughi A; Mehrabadi M; Kouhkan F
    Sci Rep; 2024 Jun; 14(1):13542. PubMed ID: 38866824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
    Chen Y; Song W; Gao Y; Dong X; Ji X
    Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Sp N; Kang DY; Lee JM; Jang KJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
    Jiang K; Zou H
    Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
    Zhang N; Fan J; Deng Z
    Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo.
    Li J; Zhong X; Zhao Y; Shen J; Xiao Z; Pilapong C
    Sci Rep; 2024 Jan; 14(1):2348. PubMed ID: 38287075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis.
    Li S; Mei Z; Hu HB; Zhang X
    J Cell Physiol; 2018 Sep; 233(9):6679-6688. PubMed ID: 29215698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-125a regulates HAS1 and inhibits the proliferation, invasion and metastasis by targeting STAT3 in non-small cell lung cancer cells.
    Huang H; Huang J; Yao J; Li N; Yang Z
    J Cell Biochem; 2020 Jun; 121(5-6):3197-3207. PubMed ID: 31930562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-130a enhances the killing ability of natural killer cells against non-small cell lung cancer cells by targeting signal transducers and activators of transcription 3.
    Zhou X; Liu S; Liu J; Zhang Z; Mao X; Zhou H
    Biochem Biophys Res Commun; 2020 Mar; 523(2):481-486. PubMed ID: 31883616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-454 inhibits non‑small cell lung cancer cells growth and metastasis via targeting signal transducer and activator of transcription-3.
    Liu S; Ge X; Su L; Zhang A; Mou X
    Mol Med Rep; 2018 Mar; 17(3):3979-3986. PubMed ID: 29286124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.